HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke

References

• Moonis M, Fisher M. Antiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attack. Expert Rev. Cardiovas. Therapyl, 611–615 (2003).
   Google Scholar
• Dalmay F, Mazouz H, Allard J, Pesteil F, Achard JM, Fournier A. NonAT(1)-receptor-mediated protective effect of angiotensin against acute ischemic stroke in the gerbil. j Renin Angiotensin AMosterone Syst. 2, 103–106 (2001).
   PubMed Web of Science ®Google Scholar
• Gerstein HC. Diabetes and the HOPE study: implications for macrovascular and microvascular disease. int. j Clin. Pract. (Suppl.), 8–12 (2001) .
   Google Scholar
• Vespasiani Gentilucci U, Picardi A. Ramipril and new therapeutic possibilities for ACE-inhibitors. Clin. Ter 151, 307–308 (2000).
   PubMedGoogle Scholar
• The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. Can. Cardio1.12,127 —137 (1996).
   Google Scholar
• PROGRESS — Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Progress Management Committee. Hypertens. 17,1647-1655 (1999).
   Google Scholar
• Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez F Lechat P Differential effects oflipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch. Intern. Med 163, 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• •Discusses in detail the major prospective trials of statins in a meta-analysis framework, with a discussion on lipid-lowering drugs and the differential additive effects of statins.
   Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl. Med. 339, 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Ansell BJ. Cholesterol, stroke risk and stroke prevention. CUI7: Atheroscler. Rep. 2, 92–96 (2000).
   Google Scholar
• Plehn JF, Davis BR, Sacks FM et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 99, 216–223 (1999).
   PubMed Web of Science ®Google Scholar
• ••First study to demonstrate a significantrisk reduction in recurrent ischemic stroke where stroke was a prespecified end point.
   Google Scholar
• Sever PS, Dahlof B, Poulter NR et al Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo—Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet361, 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• •Demonstrates a significant effect of statins in secondary stroke prevention in hypertensive hyperlipidemic patients.
   Google Scholar
• Hennekens CH. The ALLHAT-LLT and ASCOT-LLA trials: are the discrepancies more apparent than real? CUI7: Atheroscler. Rep. 6, 9–11 (2004).
   Google Scholar
• Kulbertus H, Scheen AJ. Clinical study of the month. The ALLHAT-LLT Trial. Rev Med. Liege 58, 53–58 (2003).
   PubMedGoogle Scholar
• Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) .161/1//A 288, 2998–3007 (2002).
   Google Scholar
• •A negative statin study but demonstrates the same trends as the other positive trials.
   Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD et al Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285, 1711–1718 (2001).
   PubMed Web of Science ®Google Scholar
• Byington RP, Jukema JW, Salonen JT et al Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 92, 2419–2425 (1995).
   Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• ••Largest and most conclusive study thatdemonstrated a robust effect of simvastatin in secondary stroke prevention. The benefits were equally evident in patients without ischemic heart disease as well as in the older (>75 years) population.
   Google Scholar
• Deanfield JE. Clinical trials: evidence and unanswered questions —hyperlipidemia. Cerebrovasc. Dis. 16\(Suppl. 3), 25–32 (2003).
   Google Scholar
• Kagansky N, Levy S, Knobler H. The role of hyperglycemia in acute stroke. Arch. Neural 58, 1209–1212 (2001).
   PubMedGoogle Scholar
• Auer RN. Nonpharmacologic (physiologic) neuroprotection in the treatment of brain ischaemia. Ann. NY Acad. Sci. 939, 271–282 (2001).
   PubMed Web of Science ®Google Scholar
• Ginsberg MD, Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. Stiake 29, 529–534 (1998).
   PubMed Web of Science ®Google Scholar
• Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke 32, 1112–1115 (2001).
   PubMed Web of Science ®Google Scholar
• •Demonstrated a trend towards improved outcome after acute ischemic stroke, not observed in any prior study.
   Google Scholar
• Moonis M, Kane K, Fisher M. Factors predictive of short-term functional outcome of acute ischemic stroke. Proceedings of the Asia Pacific Conference, 203 (2002).
   Google Scholar
• Moonis M, Kane K, Fisher M. Poststroke statins improve outcome after acute ischemic stroke. Neurology60\(Suppl. 1), S37 (2003).
   Google Scholar
• Endres M, Laufs U, Huang Z et al Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Floc Natl Acad Li USA 95, 8880–8885 (1998).
   PubMed Web of Science ®Google Scholar
• Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Shake 32, 980–986 (2001).
   Google Scholar
• Laufs U, Gertz K, Huang P et al Atorvastatin upregulates Type III nitric oxide synthase in thrombocytes, decreases platelet activation and protects from cerebral ischaemia in normocholesterolemic mice. Stroke 31, 2442–2449 (2000).
   PubMed Web of Science ®Google Scholar
• Sironi L, Cimino M, Guerrini U et al Treatment with statins after induction of focal ischaemia in rats reduces the extent of brain damage. Arterioscler. Thiamb. Vasc. Biol. 23, 322–327 (2003).
   PubMed Web of Science ®Google Scholar
• Balduini W, De Angelis V, Mazzoni E, Cimino M. Simvastatin protects against long-lasting behavioral and morphological consequences of neonatal hypoxidischemic brain injury. Stroke 32, 2185–2191 (2001).
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang ZG, Li Y et al Statins induce angiogenesis, neurogenesis and synaptogenesis after stroke. Ann. Neural 53, 743–751 (2003).
   PubMed Web of Science ®Google Scholar
• ••An important experimental study demonstrating possible mechanisms (enhanced recovery), by which statins may improve after acute ischemic stroke.
   Google Scholar
• Home BD, Muhlestein JB, Carlquist JF et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. jAm. Coll Calrlial 36, 1774–1780 (2000).
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa E Inflammation, statins and outcome after ischemic stroke. Stroke 32, 2446–2447 (2001).
   PubMed Web of Science ®Google Scholar
• •Good paper that discusses the other properties of statins besides their lipid lowering effect, that may be the basis of neuroprotection.
   Google Scholar
• Kinlay S, Schwartz GG, Olsson AG et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108, 1560–1566 (2003).
   PubMed Web of Science ®Google Scholar
• Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA, Jr. interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J: Exp. Med. 160, 618–623 (1984).
   Google Scholar
• Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 128, 11–18 (1997).
   Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360, 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• Vaughan CJ, Delanty N, Basson CT Do statins afford neuroprotection in patients with cerebral ischaemia and stroke? CNS DITIF 15, 589–596 (2001).
   PubMed Web of Science ®Google Scholar
• Vaughan CJ, Delanty N, Basson CT Statin therapy and stroke prevention. CUI7: Opin. Calrlial 16, 219–224 (2001).
   Google Scholar